DeepCure

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Venture capital investment in biopharmaceutical companies ticked higher in the first quarter of 2024. In the second quarter, money is flowing into VC investors and funds focused specifically on the li

Artificial intelligence and machine learning (AI/ML) have become indispensable tools for uncovering new drug targets and ways to hit them with small and large molecules of all kinds. Speakers at the r

Arbor Biotechnologies , Acrivon Therapeutics Inc. and bit.bio are the newest members of the biopharma venture capital mega-round club after the companies announced series B rounds totaling $215m, $100